BioSpace News Archive

Neovasc Inc., a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, the Tiara™, and minimally invasive devices for the treatment of refractory angina, the Neovasc Reducer™ reported financial results for the fourth quarter and full year ending December 31, 2019.

Marrone Bio Innovations, Inc. announced that its Form S-1 resale registration statement relating to the potential resale of shares of common stock, including common stock issuable upon the exercise of warrants, held by certain shareholders of the Company has been declared effective by the U.S.

Agios Pharmaceuticals, Inc. announced that the European Medicines Agency Committee for Orphan Medicinal Products issued a positive opinion on the company’s application for orphan drug designation for its investigational medicine mitapivat as a potential treatment for pyruvate kinase deficiency, a rare, debilitating, hemolytic anemia.

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint results from the ongoing Phase 2a BALANCED study of AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis, or NASH, in a pre-market press release and webcast to be held on Tuesday, March 31, 2020.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody® therapeutic technology platform, today announced the achievement of a clinical milestone in conjunction with the CX-2029 program, triggering a $40 million payment from AbbVie to CytomX.

INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, today announced financial results for the year ended December 31, 2019.

Haemonetics Corporation (NYSE: HAE) today announced that it has appointed Anila Lingamneni Executive Vice President and Chief Technology Officer, effective April 1, 2020

Savara Inc., an orphan lung disease company, provided an update on the impact COVID-19 has had on two of the Company’s clinical studies in cystic fibrosis.

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today shared an update on its response to the COVID-19 pandemic and a current assessment of the impact on AVROBIO’s operations.

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifying therapies for neurodegenerative and cardiometabolic diseases, today announced financial results for the year ended December 31, 2019 and provided a corporate strategic update.